

MRN: _____

DOB: _____

STANDARD RENFLEXIS (infliximab-abda) PLAN OF TREATMENT

NOTE: Patient *may be ineligible* to receive (infliximab-abda) if receiving antibiotics for active infectious process, antifungal therapy, active fever and/or suspected infection, new or worsening symptoms of CHF, new-onset or deterioration neurological changes, and/or surgery.

1. Patient Name: _____ Height (inches): _____ Weight (lbs): _____

2. Allergies: _____

3. Diagnosis: ICD-10 Code: _____ **Diagnosis Description:** _____

4. Pre-medications: Administered 30 minutes prior to infusion as selected:

**Product information suggests premedication of antihistamines, acetaminophen, and/or corticosteroids.*

Acetaminophen: <input type="checkbox"/> 650mgs PO <input type="checkbox"/> 500mgs PO <input type="checkbox"/> 325mgs PO	Diphenhydramine: <input type="checkbox"/> 25 mgs PO, <input type="checkbox"/> 50mgs PO, <input type="checkbox"/> 25 mgs IVP, <input type="checkbox"/> 50mgs IVP or Alternate oral antihistamine to diphenhydramine: <input type="checkbox"/> Cetirizine 10 mg, <input type="checkbox"/> Loratadine 10 mg, Fexofenadine <input type="checkbox"/> 60mgs or <input type="checkbox"/> 180mgs Methylprednisolone <input type="checkbox"/> 40mgs IVP <input type="checkbox"/> 125mgs IVP or other _____mgs IVP Famotidine: <input type="checkbox"/> 20mgs PO, <input type="checkbox"/> 40mgs PO, <input type="checkbox"/> 20mgs IVP, <input type="checkbox"/> 40mgs IVP
--	---

Pre-medicate with other: _____

5. Dose: RENFLEXIS (infliximab-abda) infused via pump with 0.22 micron filter

_____ 3 mg/kg per 250 ml Sodium Chloride 0.9% IV to infuse over at least 2 hours **OR**

_____ Other Dose: _____ mg or _____ mg/kg per 250 - 500 ml Sodium Chloride 0.9% IV

6. Frequency:

_____ Induction orders to be completed at 0 week, 2 week, and 6 weeks, and then every 8 weeks

_____ Orders every 8 weeks (maintenance)

Special orders: _____

If adverse drug reaction occurs, utilize the ADVERSE DRUG REACTION GUIDELINES

7. Physician's Signature: _____ / _____ Date: _____

No Stamp Signatures

(Dispense as written)

(Substitution permitted)

Printed Physician's Name with Credentials: _____ NPI: _____

MRN: _____

DOB: _____

Standard Guidelines for Prescribing RENFLEXIS (infliximab-abda)

(Required documentation with all initial referrals)

Patient Name: _____

Referral Date: _____

____ Include signed and completed **Plan of Treatment**.

____ Include patient demographic information and insurance information. (Copy of insurance cards if available)

____ **Supporting clinical MD notes to include any past tried and/or failed therapies, intolerance, outcomes or contraindications to conventional therapy. Include any lab results and/or tests to support diagnosis.**

____ If patient is switching biological therapies, then MD must specify wash-out period prior to starting RENFLEXIS as specified of _____ weeks. Last known biological therapy: _____ and last date received: _____. (Include copy of last infusion record if available and currently on therapy)

____ Other as requested: _____

Pre-Screening:

____ **Required TB screening results: PPD or QuantiFERON Gold Test.**

(* If screening results are positive or indeterminate, then a negative CXR result is required.)

____ **Required Hepatitis screening to include: Hepatitis B Surface Antigen results.**

** Warnings/Precautions: ****Product information suggests that patients who have stopped treatment for an extended period are at higher risk for hypersensitivity reactions. MD should evaluate premedication and consider antibody testing prior to restart of infliximab or biosimilar.*** Patient should not have an active ongoing infection, signs or symptoms of malignancy, or invasive fungal infection. Do not initiate RENFLEXIS therapy in patients with moderate to severe Congestive Heart Failure. ***RENFLEXIS at doses of >5 mg/kg should not be administered to patients with moderate to severe heart failure.*** Patient with mild CHF should be closely monitored. Therapy should be discontinued in patients who develop new or worsening symptoms of heart failure. **Hepatotoxicity:** Stop therapy in case of jaundice and/or marked liver enzyme elevations. **Malignancies:** including lymphoma was greater in TNF blocker treated patients Due to the risk of HSTCL carefully assess the risk/benefits especially if the patient has Crohn's disease or ulcerative colitis, is male, and is receiving azathioprine or 6-mercaptopurine treatment. **Lupus-like syndrome:** stop if symptoms develop. Evaluation of immunizations should be completed prior to and live vaccines should not be given before or concurrently with RENFLEXIS. See full prescribing information.



Checklist for referrals to AccuRX Infusion Center:

Fax referral to 1-866-990-3192

- Patient demographics – address, phone number, SS#, etc.
- Insurance Information – copy of the card(s) if possible
- Plan of Treatment/Orders
- Most recent physician office notes to include tried and failed therapies – all insurance companies that require a pre-authorization require the note. This includes Medicare/Medicaid HMOs
- Any lab results or other diagnostic procedures to support the diagnosis

AccuRx Infusion Center will complete insurance verification and submit all required clinical documentation to the patient's insurance company for eligibility. Our office will notify you if any further information is required. We will review financial responsibility with the patient and refer them to any available Co-pay assistance as required. Thank you for the referral.